The NSABP B-47/NRG trial is a randomized phase III study of the add-on effect of trastuzumab, a humanized HER2 monoclonal antibody, on two standard regimens for HER2-low, high-risk, primary invasive breast cancers. This evidence concerns the gene ERBB2 and invasive breast carcinoma.